Skip to content
Peptide research

ANP

Also known as Atrial Natriuretic Peptide · Atriopeptin · ANF
Category
Cardiovascular
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A naturally occurring 28-amino-acid hormone used in hospitals to rapidly offload a failing heart in acute heart failure, not marketed for wellness or longevity. Its blood-pressure and pulmonary-pressure-lowering effects are well established in humans, but easing breathlessness is only weakly supported, and it has never shown a mortality benefit. The main danger is hypotension. It is a regulated acute-care infusion, not a research-grade peptide.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Rapid reduction in pulmonary capillary wedge pressure in acute heart failure

    High

    Phase III RCT in 477 patients showed rapid drop in wedge pressure at 1 hour.

  • Improvement in dyspnea (breathlessness) in acutely decompensated CHF

    Speculative

    Largest placebo-controlled RCT missed its dyspnea endpoint; symptom benefit remains unproven.

  • Vasodilation and blood pressure reduction through cGMP-mediated smooth muscle relaxation

    High

    Blood pressure lowering is well documented in human RCTs; hypotension is the dose-limiting effect.

Evidence limits

Evidence Level
Moderate

ANP has human trial evidence and carperitide has been approved in Japan since 1995. A 477-patient rhANP trial found transient pulmonary-pressure improvement without significant dyspnea or mortality benefit. VMAC and ASCEND-HF studied BNP/nesiritide and provide related-peptide evidence, not direct ANP evidence: nesiritide was FDA-approved in 2001 on the VMAC trial, and the ASCEND-HF trial (n=7141) showed no mortality benefit. BNP and NT-proBNP levels are guideline-recommended biomarkers for heart failure diagnosis.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Hypotension (dangerously low blood pressure)

    High
  • Worsening renal function

    Moderate
  • No mortality benefit despite hemodynamic effects

    High
  • Headache and nausea

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.